--- schema_version: "secwatch.filing_event.v1" accession: "0001108205-23-000022" form_type: "8-K" ticker: "CRIS" cik: "0001108205" company_name: "CURIS INC" filed_at: "2023-03-13T23:59:59+00:00" generated_at: "2026-06-18T04:13:12.074022+00:00" event_type: "earnings" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # Curis completes FDA-requested enrollment for emavusertib; FY2022 net loss $56.7M ## Summary - Completed enrollment of 9 additional patients at 200mg BID for TakeAim Leukemia study ahead of schedule; expects data in Q2, FDA meeting in Q3 for partial clinical hold resolution. - Net loss for FY2022 was $56.7M ($0.61 per share) vs $45.4M ($0.50) in 2021; Q4 net loss $11.3M ($0.12) vs $13.6M ($0.15) in Q4 2021. - Revenue from Erivedge royalties was $10.2M in FY2022 vs $10.6M; cash and investments $85.6M as of Dec 31, 2022, expected to fund operations into 2025. - R&D expenses increased to $43.3M from $34.9M in FY2022; company focused resources on emavusertib development. - Board adopted amended bylaws including exclusive forum provision and enhanced stockholder nomination requirements; advance notice deadline for 2024 annual meeting changed. ## SEC filing metadata - accession: 0001108205-23-000022 - form_type: 8-K - ticker: CRIS - cik: 0001108205 - company_name: CURIS INC - filed_at: 2023-03-13T23:59:59+00:00 - event_type: earnings - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 2.02, 5.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000022/0001108205-23-000022-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000022/cris-20230307.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001108205-23-000022 - JSON: https://secwatch.observer/filing/0001108205-23-000022.json - Plain text: https://secwatch.observer/filing/0001108205-23-000022.txt ## Key facts - Earnings Releases CURIS INC reported full year ended December 31, 2022 vs full year ended December 31, 2021 results: revenue 10.2 million vs 10.6 million, net income net loss of 56.7 million vs net loss of 45.4 million, EPS 0.61 per share loss vs 0.50 per share loss. - Period: full year ended December 31, 2022 vs full year ended December 31, 2021 - Revenue: 10.2 million vs 10.6 million - Net income: net loss of 56.7 million vs net loss of 45.4 million - EPS: 0.61 per share loss vs 0.50 per share loss - Result: reported results source text: to a net loss of $13.6 million or $0.15 per share on both a basic and diluted basis, for the same period in 2021. Revenues, net for the year ended December 31, 2022, were $10.2 million as compared to $10.6 million for the same period in 2021. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®. evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000022/0001108205-23-000022-index.htm - Earnings Releases CURIS INC reported fourth quarter ended December 31, 2022 vs fourth quarter ended December 31, 2021 results: revenue 2.9 million vs 3.1 million, net income net loss of 11.3 million vs net loss of 13.6 million, EPS 0.12 per share loss vs 0.15 per share loss. - Period: fourth quarter ended December 31, 2022 vs fourth quarter ended December 31, 2021 - Revenue: 2.9 million vs 3.1 million - Net income: net loss of 11.3 million vs net loss of 13.6 million - EPS: 0.12 per share loss vs 0.15 per share loss - Result: reported results source text: Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®. Revenues for the fourth quarters of 2022 and 2021 were $2.9 million and $3.1 million, respectively. Costs of royalties which relate to third-party university patent licensors in connection with Genentech and Roche's Erivedge net sales, for the evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000022/0001108205-23-000022-index.htm - Governance Changes CURIS INC: Amended and restated by-laws to eliminate stockholder list requirement at meetings, address remote meeting adjournment due to technical failure, add exclusive forum provision, revise advance notice deadlines and procedural mechanics for stockholder nominations and proposals, add emergency by-law pro (effective 2023-03-07). - Change: bylaw amendment - Effective: 2023-03-07 source text: On March 7, 2023, the board of directors (the “Board”) of the Company approved an amendment and restatement of the Company’s Amended and Restated By-Laws (as so amended and restated, the “Amended and Restated By-Laws”), effective immediately. evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000022/0001108205-23-000022-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.